ADPT Quote, Financials, Valuation and Earnings

Cue Biopharma, Inc. has a net margin of 10.16% compared to Adaptive Biotechnologies Corp.'s net margin of -346.58%. Adaptive Biotechnologies Corp.'s return on equity of -39.8% beat Cue Biopharma, Inc.'s return on equity of -233.04%.

Adaptive Biotechnologies Corp. has a consensus price target of $20.00, signalling upside risk potential of 10.87%. On the other hand Cue Biopharma, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 1366.28%. Given that Cue Biopharma, Inc. has higher upside potential than Adaptive Biotechnologies Corp., analysts believe Cue Biopharma, Inc. is more attractive than Adaptive Biotechnologies Corp..

Adaptive Biotechnologies Corp. has a beta of 2.177, which suggesting that the stock is 117.696% more volatile than S&P 500. In comparison Cue Biopharma, Inc. has a beta of 1.468, suggesting its more volatile than the S&P 500 by 46.764%.

Adaptive Biotechnologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cue Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies Corp. pays -- of its earnings as a dividend. Cue Biopharma, Inc. pays out -- of its earnings as a dividend.

Adaptive Biotechnologies Corp. quarterly revenues are $94M, which are larger than Cue Biopharma, Inc. quarterly revenues of $2.1M. Adaptive Biotechnologies Corp.'s net income of $9.5M is higher than Cue Biopharma, Inc.'s net income of -$7.4M. Notably, Adaptive Biotechnologies Corp.'s price-to-earnings ratio is -- while Cue Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies Corp. is 10.92x versus 4.14x for Cue Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 10.16% compared to Adaptive Biotechnologies Corp.'s net margin of 38.89%. Adaptive Biotechnologies Corp.'s return on equity of -39.8% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Adaptive Biotechnologies Corp. has a consensus price target of $20.00, signalling upside risk potential of 10.87%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $826.04 which suggests that it could grow by 9.53%. Given that Adaptive Biotechnologies Corp. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Adaptive Biotechnologies Corp. is more attractive than Regeneron Pharmaceuticals, Inc..

Adaptive Biotechnologies Corp. has a beta of 2.177, which suggesting that the stock is 117.696% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Adaptive Biotechnologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.88 per share. Adaptive Biotechnologies Corp. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adaptive Biotechnologies Corp. quarterly revenues are $94M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Adaptive Biotechnologies Corp.'s net income of $9.5M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Adaptive Biotechnologies Corp.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies Corp. is 10.92x versus 5.83x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of 10.16% compared to Adaptive Biotechnologies Corp.'s net margin of -3135.32%. Adaptive Biotechnologies Corp.'s return on equity of -39.8% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

Adaptive Biotechnologies Corp. has a consensus price target of $20.00, signalling upside risk potential of 10.87%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 44.33%. Given that Recursion Pharmaceuticals, Inc. has higher upside potential than Adaptive Biotechnologies Corp., analysts believe Recursion Pharmaceuticals, Inc. is more attractive than Adaptive Biotechnologies Corp..

Adaptive Biotechnologies Corp. has a beta of 2.177, which suggesting that the stock is 117.696% more volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Adaptive Biotechnologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies Corp. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Adaptive Biotechnologies Corp. quarterly revenues are $94M, which are larger than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. Adaptive Biotechnologies Corp.'s net income of $9.5M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, Adaptive Biotechnologies Corp.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies Corp. is 10.92x versus 44.49x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks, Inc. has a net margin of 10.16% compared to Adaptive Biotechnologies Corp.'s net margin of -70.99%. Adaptive Biotechnologies Corp.'s return on equity of -39.8% beat Zymeworks, Inc.'s return on equity of -18.82%.

Adaptive Biotechnologies Corp. has a consensus price target of $20.00, signalling upside risk potential of 10.87%. On the other hand Zymeworks, Inc. has an analysts' consensus of $35.62 which suggests that it could grow by 44.66%. Given that Zymeworks, Inc. has higher upside potential than Adaptive Biotechnologies Corp., analysts believe Zymeworks, Inc. is more attractive than Adaptive Biotechnologies Corp..

Adaptive Biotechnologies Corp. has a beta of 2.177, which suggesting that the stock is 117.696% more volatile than S&P 500. In comparison Zymeworks, Inc. has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

Adaptive Biotechnologies Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies Corp. pays -- of its earnings as a dividend. Zymeworks, Inc. pays out -- of its earnings as a dividend.

Adaptive Biotechnologies Corp. quarterly revenues are $94M, which are larger than Zymeworks, Inc. quarterly revenues of $27.6M. Adaptive Biotechnologies Corp.'s net income of $9.5M is higher than Zymeworks, Inc.'s net income of -$19.6M. Notably, Adaptive Biotechnologies Corp.'s price-to-earnings ratio is -- while Zymeworks, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies Corp. is 10.92x versus 13.87x for Zymeworks, Inc.. Usually stocks with elevated PS ratios are considered overvalued.